FLUX THROUGH THE DENOVO PYRIMIDINE PATHWAY INVIVO - EFFECT OF N-PHOSPHONACETYL-L-ASPARTATE, A POTENT INHIBITOR OF ASPARTATE-TRANSCARBAMYLASE

被引：0
|
作者：
MONKS, A
ANDERSON, LW
STRONG, J
CYSYK, RL
机构：
来源：
JOURNAL OF BIOLOGICAL CHEMISTRY | 1983年 / 258卷 / 22期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：3564 / 3569
页数：6
相关论文
共 50 条
  • [41] URIDINE ALLOWS DOSE ESCALATION OF 5-FLUOROURACIL WHEN GIVEN WITH N-PHOSPHONACETYL-L-ASPARTATE, METHOTREXATE, AND LEUCOVORIN
    SEITER, K
    KEMENY, N
    MARTIN, D
    SCHNEIDER, A
    WILLIAMS, L
    COLOFIORE, J
    SAWYER, R
    [J]. CANCER, 1993, 71 (05) : 1875 - 1881
  • [42] NEUROTOXICITY OF THE PYRIMIDINE SYNTHESIS INHIBITOR N-PHOSPHONOACETYL-L-ASPARTATE
    WILEY, RG
    GRALLA, RJ
    CASPER, ES
    KEMENY, N
    [J]. ANNALS OF NEUROLOGY, 1982, 12 (02) : 175 - 183
  • [43] CROSS RESISTANCE PROFILES OF HUMAN OVARIAN-CARCINOMA CELLS SELECTED FOR RESISTANCE TO N-PHOSPHONACETYL-L-ASPARTATE (PALA)
    CHAN, TCK
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 299 - 299
  • [44] MECHANISM OF SYNERGY BETWEEN N-PHOSPHONACETYL-L-ASPARTATE AND DIPYRIDAMOLE IN A HUMAN OVARIAN-CARCINOMA CELL-LINE
    CHAN, TCK
    HOWELL, SB
    [J]. CANCER RESEARCH, 1985, 45 (08) : 3598 - 3604
  • [45] SUPERPRODUCTION AND RAPID PURIFICATION OF ESCHERICHIA-COLI ASPARTATE-TRANSCARBAMYLASE AND ITS CATALYTIC SUBUNIT UNDER EXTREME DEREPRESSION OF THE PYRIMIDINE PATHWAY
    NOWLAN, SF
    KANTROWITZ, ER
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1985, 260 (27) : 4712 - 4716
  • [46] Insights into the mechanisms of catalysis and heterotropic regulation of Escherichia coli aspartate transcarbamoylase based upon a structure of the enzyme complexed with the bisubstrate analogue N-phosphonacetyl-L-aspartate at 2.1 Å
    Jin, L
    Stec, B
    Lipscomb, WN
    Kantrowitz, ER
    [J]. PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1999, 37 (04): : 729 - 742
  • [47] Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa
    Harte, RJA
    Matthews, JC
    O'Reilly, SM
    Tilsley, DWO
    Osman, S
    Brown, G
    Luthra, SJ
    Brady, F
    Jones, T
    Price, PM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1580 - 1588
  • [48] CLINICAL-TRIAL OF SEQUENTIAL N-PHOSPHONACETYL-L-ASPARTATE, THYMIDINE, AND 5-FLUOROURACIL IN ADVANCED COLORECTAL-CARCINOMA
    OCONNELL, MJ
    MOERTEL, CG
    RUBIN, J
    HAHN, RG
    KVOLS, LK
    SCHUTT, AJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (10) : 1133 - 1138
  • [49] PHASE I-II TRIAL OF N-PHOSPHONACETYL-L-ASPARTATE (PALA) AND 5-FLUOROURACIL (5FU)
    ERLICHMAN, C
    DONEHOWER, RC
    KLECKER, R
    CHABNER, BA
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 366 - 366
  • [50] SELECTIVE-INHIBITION OF PYRIMIDINE SYNTHESIS AND DEPLETION OF NUCLEOTIDE POOLS BY N-(PHOSPHONACETYL)-L-ASPARTATE
    MOYER, JD
    HANDSCHUMACHER, RE
    [J]. CANCER RESEARCH, 1979, 39 (08) : 3089 - 3094
12345